Under the Symbol:
Avinger to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum 2018
Wednesday, November 7, 2018 8:45 AM
REDWOOD CITY, CA / ACCESSWIRE / November 7, 2018 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD), today announced its participation at the Canaccord Genuity Medical Technologies & Diagnostics Forum 2018. The conference is being held on Thursday, November 15, 2018 at the Westin Grand Central Hotel in New York City.
Event: Canaccord Genuity Medical Technologies & Diagnostics Forum 2018
Date: Thursday, November 15, 2018
Time: 10:00-10:30 AM ET
Location: Westin Grand Central Hotel/ Track 7
Mr. Jeff Soinski, Avinger's President and CEO, will deliver a corporate presentation on the Company's Lumivascular platform, the only technology that combines real-time intravascular imaging with highly effective therapy for treatment of PAD. Mr. Soinski will also be available for one-on-one meetings with investors.
About Avinger, Inc.
Avinger is a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the anticipated closing of the offering and use of proceeds from the offering. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include our dependency on a limited number of products; our ability to demonstrate the benefits of our Lumivascular platform; the resource requirements related to Pantheris; the outcome of clinical trial results; potential exposure to third-party product liability, intellectual property and other litigation; lack of long-term data demonstrating the safety and efficacy of our Lumivascular platform products; experiences of high-volume users of our products may lead to better patient outcomes than those of physicians that are less proficient; reliance on third-party vendors; dependency on physician adoption; reliance on key personnel; and requirements to obtain regulatory approval to commercialize our products; as well as the other risks described in the section entitled "Risk Factors" and elsewhere in our quarterly Form 10-Q filing made with the Securities and Exchange Commission on August 13, 2018. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Avinger disclaims any obligation to update these forward-looking statements.
Public Relations Contact:
VP of Marketing & Business Operations
Chief Financial Officer
SOURCE: Avinger, Inc.